Related Experiment Video

Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis

Shuning Zhang1, Lei Zhang, Aijun Sun

  • 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.

European Journal of Internal Medicine
|September 20, 2011
PubMed

Insights

Statins did not significantly improve outcomes for most chronic systolic heart failure patients. However, atorvastatin and use in patients under 65 showed reduced mortality and heart failure readmissions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Conflicting evidence exists regarding the efficacy of statin therapy in patients with chronic systolic heart failure (CHF).
  • Randomized controlled trials (RCTs) have yielded varied results, necessitating a comprehensive meta-analysis.

Purpose of the Study:

  • To investigate the effect of statins on clinical outcomes in patients with chronic systolic heart failure (CHF).
  • To conduct a meta-analysis of randomized controlled trials (RCTs) to clarify statin's role in CHF management.

Main Methods:

  • A systematic literature search was performed across major databases (PubMed, MEDLINE, EMBASE, Cochrane) up to February 2011.
  • Included were RCTs comparing statin versus placebo in established CHF patients, reporting clinical outcomes.
  • Risk ratios (RR) were calculated using a random effects model for pooled analysis.

Main Results:

  • The meta-analysis included 13 trials with 10,447 CHF patients.
  • Statin treatment did not significantly reduce all-cause death (RR=0.93), cardiovascular death, pump failure, or heart failure rehospitalization (RR=0.90).
  • A trend towards reduced nonfatal myocardial infarction (RR=0.84) was observed. Atorvastatin and statin use in patients <65 years showed significant reductions in mortality and readmissions.

Conclusions:

  • Statin therapy demonstrates limited impact on overall clinical outcomes in chronic systolic heart failure patients.
  • Specific statins, like atorvastatin, and patient populations, such as those under 65, may benefit from statin treatment.
  • Statin administration is feasible in CHF patients, with potential efficacy in select subgroups.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...